Rhamnazin

Rhamnazin is a naturally occurring flavonol glycoside found in plants such as Rhamnus species and sea buckthorn, structurally characterized by a 3,5-dihydroxy-4-methoxyflavone backbone. It demonstrates bioactivity primarily through free radical scavenging, inhibition of viral proteases, and induction of apoptosis in cancer cell lines in preclinical models.

Origin & History

Rhamnazin is an O-methylated flavonol derived from quercetin, with methylation at the 3' and 7 positions. It occurs naturally in various plants including Rhamnus species (buckthorns), Artemisia species, Eucalyptus globulus, and others. The compound is biosynthesized via the flavonoid pathway and appears as a yellow powder extracted using spectral analyses.

Historical & Cultural Context

No historical or traditional medicinal uses are documented for rhamnazin. The compound has been identified as a plant-derived flavonoid of research interest only since 2001, with no references to traditional medicine systems.

Health Benefits

• May exhibit cytotoxic activity against cancer cells (preclinical evidence only, IC50 14.6-15.3 μM against KB cell line)
• Potential antioxidant effects (in vitro studies only)
• May inhibit HCV protease (preliminary laboratory evidence)
• Shows antimicrobial activity (MIC 12.5-150 μg/mL in vitro)
• Possible anti-inflammatory properties based on flavonoid structure (theoretical, no direct evidence)

How It Works

Rhamnazin exerts antioxidant effects by donating hydrogen atoms to neutralize reactive oxygen species via its catechol-like hydroxyl groups on the A and B rings of its flavone scaffold. Its cytotoxic activity against KB (HeLa derivative) cells is thought to involve disruption of the cell cycle and induction of apoptotic pathways, potentially through modulation of caspase activation, with an IC50 of approximately 14.6–15.3 μM. Inhibition of hepatitis C virus NS3/4A serine protease has been observed in cell-free assays, suggesting competitive or allosteric binding at the protease active site.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on rhamnazin. Research is limited to in vitro and preclinical studies, with the compound first documented in 2001 (PMID: 11594002) and noted as a potential biomarker in subsequent studies (PMIDs: 25704088, 27025066).

Clinical Summary

All available evidence for rhamnazin is derived from in vitro cell-based and cell-free laboratory studies; no human clinical trials have been conducted to date. Cytotoxic activity was measured against the KB squamous carcinoma cell line with IC50 values of 14.6–15.3 μM, though translation to in vivo efficacy remains undemonstrated. Antimicrobial studies report minimum inhibitory concentrations (MICs) ranging widely from 12.5 to 150 μg/mL depending on the organism and assay conditions, which limits direct comparison across studies. HCV NS3 protease inhibition has been documented in enzymatic assays only, and no animal or human data exist to support clinical application for any of these endpoints.

Nutritional Profile

Rhamnazin (3',7-di-O-methylquercetin; chemical formula C₁₇H₁₄O₇; molecular weight 330.29 g/mol) is a naturally occurring O-methylated flavonol, not a nutritional food source. It is a bioactive secondary metabolite found in trace quantities in select plant species. Key details: • Classification: Flavonol (subclass of flavonoids), specifically a dimethyl ether derivative of quercetin with methoxy groups at the 7- and 3'-positions. • Natural occurrence: Found in small amounts in Rhamnus species (buckthorn), Calliandra houstoniana, Hypericum species, and certain other medicinal plants; concentrations are typically in the range of 0.001–0.1% of dry plant weight depending on species, tissue, and extraction conditions. • No macronutrient value: As a polyphenolic compound consumed only in trace phytochemical quantities, it contributes negligible calories, protein, fat, carbohydrate, or fiber. • Bioactive compound profile: Contains the characteristic flavonoid C6-C3-C6 backbone with a 3-hydroxyflavone core; possesses a catechol-like B-ring (with one hydroxyl at 4' and one methoxy at 3'), a free 5-OH group on the A-ring (critical for metal chelation), and a 3-OH group on the C-ring. These structural features contribute to its antioxidant radical-scavenging capacity, though the dual methylation reduces polarity relative to quercetin. • Bioavailability notes: Oral bioavailability is expected to be low, consistent with other methylated flavonols. The O-methylation at positions 7 and 3' modestly increases lipophilicity (LogP ~2.3–2.6) compared to quercetin (LogP ~1.5), which may slightly improve passive membrane permeation but also increases hepatic phase I/II metabolism. Likely undergoes extensive first-pass glucuronidation and sulfation in the intestinal epithelium and liver. No human pharmacokinetic data are available; absorption and metabolism estimates are extrapolated from structurally analogous methylated flavonols (e.g., isorhamnetin, tamarixetin). Plasma concentrations following dietary exposure are predicted to be in the low nanomolar range. • Micronutrients/vitamins/minerals: None intrinsic to the isolated compound. • Solubility: Poorly water-soluble; soluble in DMSO, ethanol, and methanol. This limits formulation options and may further constrain oral bioavailability without delivery system enhancement.

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials exist. The compound is only available as a high-purity reference standard (>99% HPLC) for research purposes. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, other flavonols, vitamin C, bioflavonoids, rutin

Safety & Interactions

No human safety studies, toxicology trials, or established tolerable upper intake levels exist for isolated rhamnazin supplementation. As a flavonoid, it may theoretically inhibit cytochrome P450 enzymes (particularly CYP3A4 and CYP1A2), which could alter plasma concentrations of co-administered drugs metabolized by these pathways, though this has not been confirmed for rhamnazin specifically. Pregnant and breastfeeding individuals should avoid isolated rhamnazin supplements due to a complete absence of safety data in these populations. Individuals taking anticoagulants, antivirals, or chemotherapy agents should consult a healthcare provider before use given uncharacterized interaction potential.